Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms

Table 3

Four mutations with significant differences in mutant allele frequency between the three panels.

Cell line	Gene	Transcript	Variant	Fluidigm custom; panel	SureSeq Solid Tumour panel	Ion AmpliSeq Cancer Hotspot Panel	Sanger sequencing zygosity status
97-7	FGFR3	NM_00142.4	c.746C>G	N/A	81.4%	34.6%	Heterozygous
KU-19-19	NRAS	NM_002524.3	c.182A>G	48.2%	50.5%	86.3%	Heterozygous
J82	TP53	NM_000546.5	c.960G>C	85.7%	51.3%	N/A	Heterozygous
LUCC3	TP53	NM_000546.5	c.840_841insAA	57.7%	58.9%	96.4%	Heterozygous